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Red cell antibody problems in 1000 liver transplants 
G. RAMSEY, F, W. CORNELL, L. F. HAHN, P. LARSON, L. B. ISSITT, AND T. E. STARZL 
Liver transplant patients frequently require large amounts of blood. The frequency and 
nature of their red cell (RBC) antibody problems were examined. Records were reviewed 
in 496 adults and 286 children undergoing 1000 consecutive transplants. Twenty-two 
percent of adults and 14 percent of children had RBC alloantibodies. Antibodies of 
potential clinical significance were found before transplant in 6.3 percent of adults and 
1.0 percent of children; despite immunosuppression, they appeared 1 to 5 weeks after 
transplant in an additional 7.5 and 5.2 percent respectively. These antibodies probably 
represented secondary immune responses. Of 58 transplant patients with prior potentially 
significant antibodies, 8 required 7 to 110 units of antigen-untyped blood after 8 to 
28 units of antigen-negative blood; of these patients, one had subsequent hemolysis. 
Positive direct antiglobulin tests in 24 percent of adults and 10 percent of children 
were most often thought to be due to nonspecific adsorption of IgG. Anti-recipient 
ABO antibodies developed in 22 of 60 (37%) evaluable ABO-unmatched grafts; 13 cases 
had associated hemolysis. In all, 36 percent of adults and 20 percent of children had 
diverse RBC antibody problems. Resolution of these problems is an important part of 
the laboratory support necessary for a liver transplantation program. TRANSFUSION 
1989;29:396-400. 
THE BLOOD BANK plays an important role in the 
supportive care of liver transplant patients before, dur-
ing, and after surgery. Before transplant for end-stage 
liver disease, patients are often transfused for bleed-
ing due to portal hypertension, esophageal varices, 
deficient coagulation factors, thrombocytopenia, or 
other surgery. After transplant, many patients need 
further transfusions and some require retransplanta-
tion. The liver transplant program at the University 
of Pittsburgh has the world's largest such experience, 
and since the program's inception in 1981, its overall 
perioperative and postoperative blood use has been 
carefully documented.1- s These patients have ample 
opportunity for red cell (RBC) alloimmunization. 
The purpose of this study was to examine all RBC 
antibody problems encountered in 1000 consecutive 
liver transplants performed in our center from Febru-
ary 1981 to February 1987. Previously, as part of an 
examination of the relationship of the HLA system 
to RBC alloimmunization,6 we reported a 9.5 percent 
frequency of potentially significant RBC alloantibod-
ies in 263 adults. We present here our cumulative 
experience in both adults and children with regard to 
1) the overall frequencies of RBC antibodies; 2) the 
onset and duration of significant RBC antibodies rel-
ative to transplant immunosuppression; 3) the cases 
in which insufficient compatible blood was available 
for surgery; and 4) the frequencies and causes of pos-
itive direct antiglobulin tests (DATs) in these patients, 
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including an update of our previous series of ABO an-
tibodies of graft origin.? We have found that 36 per-
cent of adults and 20 percent of children undergoing 
liver transplantation have one or more RBC antibody 
problems at some point during their hospital course. 
Materials and Methods 
We examined retrospectively the records in our Cen-
tral Blood Bank transfusion service for 782 patients 
undergoing 1000 consecutive liver transplants from Febru-
ary 1981 to February 1987. Children and adults under-
went transplantation at Children's Hospital of Pittsburgh 
and Presbyterian-University Hospital, respectively. Previ-
ous transfusion histories were usually unavailable owing to 
referral from distant hospitals. Patient diagnoses, surgical 
and anesthetic techniques, and overall outcomes have been 
described.8,9 Immunosuppression consisted of cyclosporine, 
corticosteroids, and adjunctive rabbit antilymphocyte glob-
ulin or monoclonal OKT3 antibody.lO,ll The average post-
transplant hospitalization was 4 to 6 weeks. When patients 
received potentially incompatible blood at transplant or had 
positive DATs due to alloantibodies or graft-origin ABO an-
tibodies, their charts were reviewed for evidence of concur-
rent hemolysis, that is, for otherwise unexplained decreases 
in hematocrit and increases in serum indirect bilirubin. 
Our antibody screen employed two cells with an auto-
control and was read at immediate-spin, after 30 minutes 
at 37° C in saline, and then with antiglobulin reagent. In 
1986, the antiglobulin reagent was changed from a polyspe-
cific reagent to anti-IgG and the autocontrol was replaced 
by a DAT. Until 1985, positive autocontrols, associated with 
positive DATs due to IgG sensitization, led to elution stud-
ies in all cases; since then elution studies have been done 
only when transfusions were given in the past month, when 
the transfusion history was unknown, when possible hemol-
ysis was reported, or when ABO antibodies were suspected. 
Crossmatch procedures were similar to those for the screen 
until 1985, when only immediate-spin crossmatches were 
used for patients without evidence of irregular antibodies. 
Antibodies were identified with untreated and ficin-treated 
RBC panels. 
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All transplant candidates were typed and screened at 
our center on initial evaluation and usually on each sub-
sequent admission. At surgery, which typically took place 
on 4 to 8 hours' notice, 20 units of RBCs were initially 
crossmatched for adults and 10 units for children. For pa-
tients with potentially significant RBC antibodies, blood 
lacking the offending antigens (antigen-negative) could be 
sought with our blood center computer system (Model 3000, 
Hewlett-Packard, Corvallis, OR), which has provisions for 
seeking known donor phenotypes in the current inventory 
(System software, Blood Center of Southeastern Wisconsin, 
Milwaukee, WI). RBCs and fresh-frozen plasma were gen-
erally used in equal amounts until 1986, when the blood 
inventory for adults was changed so that the most common 
types, groups B Rh+, 0, and A, could usually receive their 
first 20 units as modified platelet-poor whole blood. The 
organ donor's ABO type was noted on the recipient's blood 
bank record. 
Statistical comparisons employed the chi-square test or 
Fisher's exact test with significance at p < 0.05. 
Results 
We analyzed RBC antibody problems for 496 adults re-
ceiving 616 liver transplants and for 286 children receiving 
384 transplants. The overall frequencies of clinically signifi-
cant and insignificant RBC antibodies in adults and children 
are shown in Table I. The most common potentially signif-
icant antibodies (n = 130) were anti-K (n = 45), -E (40), 
-D (14), and -Jka (9). Fifty-two patients had one potentially 
significant antibody, 25 had two, 8 had three, and I had 
four. The overall frequency of potentially significant anti-
bodies in adults, 13.7 percent, is somewhat higher than that 
in our earlier report (9.5%),6 mainly because the frequency 
has risen in recent years. The 1985 to 1987 frequency in 
adult patients was 16.9 percent. The most common clini-
cally insignificant antibodies (n = 92) were cold agglutinins 
(n = 31), high-titer low-avidity antibodies (20), and anti-M, 
-Lua, and -Bg (7 each). 
We found, or knew of, RBC antibodies of potential clin-
ical significance prior to the first transplant in 31 adults 
(6.3%) and 3 children (1.0%) (Table l). In 24 of these 34 
cases, we identified the antibodies before the day of trans-
plant; other centers informed us of two patients in whom no 
antibodies were detected by us. Another 37 adults (7.5%) 
and 15 children (5.2%) developed such antibodies after their 
first transplant; blood usage in these transplants averaged 
9 units of RBCs in children and 19 in adults, which was 
no different than usual.4 Posttransplant antibodies were all 
found 1 to 5 weeks later, except for three patients in whom 
antibodies Canti-K [n = 3] and -E [n = 1]) were found at 
7 weeks to 4.5 months after transplant. Eleven percent of 
retransplants were preceded by potentially significant RBC 
antibodies in both adults (13/120) and children (11/98); 
these totals include third transplants in 20 adults and 14 
children and fourth transplants in 1 adult and 1 child. 
The frequency of potentially significant RBC antibodies 
was analyzed according to patient sex and diagnosis. Fe-
males had higher rates than males in both pediatric (8 vs. 
4%) and adult (15 vs. 11 %) patients. The latter difference 
was due to primary biliary cirrhosis (PBC), which occurs 
mainly (90%) in women and accounts for 40 percent of our 
adult female transplant patients. Twenty percent of women 
with PBC had potentially significant RBC antibodies, com-
pared to 12 percent of non-PBC women. On the other hand, 
adults who underwent transplantation for hepatic neoplasms 
(7% of our adult patients) had a low rate (3%) of poten-
tially significant RBC antibodies. None of these differences 
reached statistical significance. No other diagnoses exhib-
ited any trends different from the overall pediatric or adult 
rates. 
In our general hospital population, we previously studied 
the frequency of loss of alloantibodies over time, and found 
that 29 percent of 170 potentially clinically significant an-
tibodies, were undetected on screenings done at least one 
month later. 12 In liver transplant patients analyzed similarly, 
14 of 28 (50%) such antibodies were lost before surgery, 
and 9 of 14 (63%) antibodies present at surgery were lost 
Table 1. Frequencies of RBC antibody problems. in 782 liver transplant patients receiving 1000 liver transplants 
Adults (n = 496) Children (n = 286) 
Before After Before After 
Antibody problem' transplant transplant Total Percentage transplant transplant Total Percentage 
Alloantibodies 60 50 110 22.2 16 24 40 14.0 
Significant 31 
-
37 68 13.7 3 15 18 6.3 
Insignificant 42 ~ 20 62 12.5 13 9 22 7.7 
-Othert ·0 1 1 0.2 1 1 2 0.7 
Positive DA T 44 74 118 23.8 5 23 28 9.8 
Nonreactive eluate 25 34 59 11.9 4 6 10 3.5 
Pan reactive eluate 3 1 4 0.8 1 0 1 0.3 
No eluate 14 4 18 3.6 0 0 0 0.0 
Alloantibody 1 8 9 1.8 0 5 5 1.7 
Delayed 1 7 8 0 4 4 
Anti-D in Rh+ 0 1 1 0 1 1 
Graft ABO antibody 0 13 13 2.6 0 7 7 2.4 
Passive ABO antibody 0 10 10 2.0 0 3 3 1.0 
Othert 1 8 9 1.8 0 2 2 0.7 
All problems 99 80 179 36.1 20 37 57 19.9 
• Patients with multiple problems are counted in each individual category. 
t Anti-D from Rh immune globulin (1 child) or of uncertain transient nature in 2 Rh+ patients who are also included below in DAT 
alloantibodies. 
t IgG and C3 (n = 3). C3 (n = 6; 4 adults and both children). or not tested monospecifically (n = 2). 
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afterward (both values, p < 0.01, compared to the previous 
study). Our earlier data suggested that children hada higher 
rate of antibody loss; this would help explain why we did 
not detect antibodies until soon after transplant, when they 
were presumably restimulated, in 15 of our 18 significantly 
alloimmunized pediatric patients. 
There were 58 transplant patients in whom significant 
antibodies were known previously. Because of urgent need, 
eight of these patients required RBCs or whole blood that 
had not been fully typed for the antigen(s) in question. This 
blood was issued after 8 to 28 units of antigen-negative 
RBCs were given. These eight cases are detailed in Table 2. 
Four of these patients survived the hospitalization. The 
number of antigen-positive units given was estimated from 
the expected phenotype frequencies of the untyped blood. 
Patient 1 was the only one to receive a large number (18 
units) of antigen-negative RBCs at the end of the case. 
Only Patient 4 had evidence of subsequent hemolysis due 
to anti-Fy' that was found 17 days postoperatively, after 
the hematocrit had dropped from 39 to 22 percent over 
1 week without bleeding. This 14-year-old girl received the 
fewest untyped units but was also the only one of the group 
with the full combination of antibody present at surgery, 
antigen-untyped blood given at the end of the case, and 
long-term survival. 
Table 1 shows the frequency of positive DATs in adults 
and children. Of the 782 patients, 146 (18.6%) had positive 
DATs. As 69 of these latter patients had nonreactive eluates, 
it was thought that a major cause of their positive DATs 
was the nonspecific adsorption of IgG onto the RBCs. Five 
eluates reacted with all RBCs tested, and in 18 cases eluates 
were not prepared when few clinically significant results 
were expected (see Methods). 
In the 14 cases in which alloantibodies were found by 
elution, we sought evidence of hemolysis in 13; one pa-
tient's chart could not be located. Ten patients had delayed 
antibody responses to K (n = 6), E (3), Jka (3), and M 
(1), but only one adult had clinical hemolysis, which was 
due to anti-Jka. This patient had two transplants in 3 days 
and then a week later had a 2-day hematocrit drop from 
34 to 19 percent, a rise in serum indirect bilirubin from 
4 to 17 mg per dl, and no detectable serum haptoglobin. 
Hemolysis also occurred in the pediatric patient who re-
ceived Fy(a)-incompatible RBCs (Patient 4 above). 
The transplantation of ABO-unmatched grafts, with the 
potential to produce ABO antibodies of graft origin, de-
clined from 17.8 percent of all transplants in 1981 to 
19847 to 4.8 percent in 1986 and 1987; such grafts have 
fared worse than ABO-matched ones,l3 Twenty-two of 
60 (37%) evaluable ABO-unmatched grafts produced def-
inite or probable anti-recipient ABO antibodies, as origi-
nally defined.7 Of the 22 grafts producing antibodies in 20 
patients, 3 could not be evaluated for hemolysis because 
of concurrent gastrointestinal hemorrhage or prior use of 
group a RBCs. Thirteen of the other 19 (68%) antibodies 
caused hemolysis, with an average hematocrit drop of 18 
percentage points (standard deviation, 6%; range, 11-30%). 
We have never observed such antibodies in group A-to-B or 
group B-to-A liver transplants, but graft survival is poor in 
these patients because of ABO incompatibility.14 
In all, 36 percent of adults and 20 percent of children had 
at least one RBC antibody problem. 
Discussion 
Patients undergoing liver transplants often are 
heavily transfused. The overall frequencies of RBC 
alloantibodies of potential clinical significance in 
our study-14 percent in adults and 6 percent in 
children-are analogous to those reported in other 
conditions such as gastrointestinal bleeding (8%) and 
chronic renal failure (7_10%).6,15 Obtaining a type 
and screen has been a helpful part of our pretrans-
plant evaluation. Of 58 total transplants in which the 
patient had significant antibodies, only 10 cases (8 
first transplant, 2 second) were not known to us until 
the day of surgery. 
Blomqvist et a1. 16 found clinically significant RBC 
antibodies in 8 of 18 (44%) adult liver transplant pa-
Table 2. Patients with previous significant RBG al/oantibodies receiving antigen-untyped blood at liver transplant 
Patient Antibodies 
1 c, E 
2 c, E, Fyb 
3 E, (K, Jka)11 
4 c, E, FyB 
5 (E) 
6 (E, K, JkB) 
7 (K) 
8 (K) 
• Antigen-negative. 
t Antigen-untyped. 
:j: No. 
§ 51 c(-), E(-). 
Initial 
Ag-Neg' 
27 
10 
8 
18 
28 
10 
26 
20 
Units of RBCs 
Estimated 
UTt Ag-Pos 
110 86 
74§ 64 
36 30 
T~ 4 
50 15 
35tt 29 
11 1 
11 1 
II ( ): Previously present but not detected at surgery. 
~ c(-), E(-) . 
•• Yes. 
tt 10 E(-). 
Final 
Ag-Neg 
18 
4 
4 
Total 
used 
155 
84 
44 
25 
78 
45 
41 
35 
Antibody 
in eluate 
Anti-E 
N 
N 
Anti-FyB 
N 
B (passive) 
N 
N 
After transplant 
Clinical Patient 
hemolysis survival 
N:j: Died 26 days 
N Died 6 days 
N Died 7 days 
Y" Y 
N Y 
N Y 
N Y 
N Died 48 days 
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tients. In the first 83 liver transplant patients (nearly 
all adults) at the Mayo Clinic, 12 (14%) had signifi-
cant antibodies before operation and 5 (6%) formed 
such antibodies afterward. 17 
Many potentially significant antibodies in our study 
were first detected by us after transplantation, de-
spite the immunosuppressive regimen involved. For 
the following reasons, we suspect that most of these 
antibodies represented secondary immune responses. 
First, as we have noted with regard to graft-origin 
ABO antibodies,7 cyclosporine is less effective against 
secondary than primary immune responses. Second, 
nearly all of these posttransplant antibodies were 
found within 5 weeks, in contrast to primary Rh 
isoimmunization, in which anti-D generally does not 
appear for 2 to 6 months. Third, in another study 
we have found that primary anti-D formation was 
detected infrequently after multiple Rh-incompatible 
RBC transfusions in organ transplant patients. 18 Some 
of these posttransplant antibodies may have been de-
tected elsewhere previously and subsequently lost be-
fore transplant. Hence, the availability of information 
from the referring hospital would be desirable. How-
ever, the clinical impact of these posttransplant an-
tibodies was limited with regard to delayed hemo-
lysis. We excluded the case of anti-M because it is 
not usually clinically significant. This left nine pa-
tients who had alloantibodies of potential clinical sig-
nificance eluted from circulating RBCs, but only one 
of the eight evaluable cases had clinical hemolysis. 
Hyma et aLl9 observed a case of immune hemoly-
sis due to multiple patient alloantibodies appearing 9 
days after liver transplant. 
Eight patients with previously detected, potentially 
significant RBC antibodies were transfused urgently 
with RBCs untyped for the offending antigen(s). De-
layed clinical hemolysis occurred in one patient. 
There are a number of possible reasons that most of 
these transfusions did not cause complications. Four 
of these patients had lost their previous antibodies by 
the time of surgery. Circulating antibodies in the oth-
ers were presumably washed out to a large extent by 8 
to 27 initial units of antigen-negative RBCs and other 
fluids. The corticosteroid regimen may have sup-
pressed postoperative extravascular immune RBC 
destruction. Also, two patients died early, before 
hemolysis might have ensued. Saving some antigen-
negative units for the end of surgery is desirable and 
was attempted in several of our cases, but the proper 
timing proved difficult to estimate. Thompson et a1. 20 
suggested that when sufficient antigen-negative blood 
cannot be obtained for patients with multiple anti-
bodies, consideration should be given first to avoid-
ing antibodies that can fix complement and thus po-
tentially cause intravascular hemolysis. Intraoperative 
blood salvage can also be of benefit in transplant cases 
with difficult RBC antibodies.21 
Positive D A Ts were due to a number of reasons but 
were thought most commonly to be due to nonspe-
cific adsorption of IgG onto the RBCs. Toy et aI.22 
described an association of positive OATs, nonre-
active eluates, and elevated serum immunoglobulins 
in patients with liver disease or infection; they sug-
gested that the IgG was nonspecific ally adsorbed onto 
the RBC membrane. In our ABO-unmatched trans-
plants, the occurrence of graft-origin ABO antibodies 
to the recipient's RBCs declined recently, both be-
cause fewer such cases were done and because the fre-
quency of antibody appearance in 1986 and 1987 de-
creased to 1 in 10 cases. In 20 ABO-unmatched liver 
transplant patients of Jenkins et a1.,23 4 had hemo-
lysis and 2 others had possible antibodies. Steininger 
et a1.24 noted hemolysis in 2 of 11 patients. On the 
other hand, Angstadt et aI.25 and Badosa et aI.26 ob-
served hemolysis after all nine ABO-unmatched he-
patic grafts in their combined series. IgG allotyp-
ing has demonstrated the donor origin of such 
antibodies from liver and renal transplants.27.28 We 
found no non-ABO antibodies of graft origin and 
no Rh immunization attributable to Rh-incompatible 
grafts, both of which have been observed after renal 
transplantation.29-33 
The extensive blood needs of liver transplant pa-
tients are frequently complicated by a diverse range 
of RBC antibody problems. Resolution of these prob-
lems is an important part of the laboratory support 
necessary for a liver transplantation program. 
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